amoxicillin 1 g and rabeprazole 20 mg) or BQT (bismuth potassium citrate 240 mg, clarithromycin 500 mg, amoxicillin 1 g and rabeprazole 20 mg) treatment, twice a day for 14 days. The efficacy endpoint ...
Metronidazole (Flagyl) 500 mg orally twice a day for 7 days Metronidazole ... then 2.5 million units IV every 4 h until delivery Ampicillin-sulbactam (Unasyn) 2 g IV initial dose, then 1 g ...
Cefazolin* (Ancef) 2 g IV initial dose then 1 g IV every 8 h until delivery Clindamycin †900 mg IV every 8 h until delivery Erythromycin †500 mg IV every 6 h until delivery If PCN allergic ...
b. Enterococcal endocarditis: Streptomycin in doses of 1 g twice daily for 2 weeks and 500 mg twice daily for an additional 4 weeks is given in combination with penicillin. Ototoxicity may require ...
and Clavam 625 (amoxicillin and potassium clavulanate tablets), labelled as manufactured by Alkem Health Science; Ciprodac 500 (ciprofloxacin tablets) from Cadila Pharmaceuticals; Zerodol-SP ...
metformin hydrochloride 500 mg, manufactured by Swiss Biotech Parenterals that helps to control the amount of glucose (sugar) in blood; diclofenac sodium tablets manufactured by Hindustan ...
Pelvic Inflammatory Disease (mild to moderate): Adults - IM 250 mg given IM as a single dose with doxycycline 100 mg orally twice daily for 14 days, with or without metronidazole 500 mg orally ...
In addition to these, the list featured Metformin tablets from Swiss Biotech Parentarels, Calcium 500 mg with Vitamin D3 ... by Aristo Pharmaceuticals, and Amoxicillin and Potassium Clavulanate ...
H9C2 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin in a 37 ... dehydrogenase 2 (MDH2) antibody ...
at 50 mg/kg/d for 14 days. The patient’s condition improved and we discharged her after several weeks in hospital. Because she had acute rheumatic fever with carditis, we prescribed secondary ...
Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...